• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Marinus Pharmaceuticals Inc.

    6/6/24 4:55:29 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRNS alert in real time by email
    S-8 1 mrns-20240606xs8.htm S-8

    As filed with the Securities and Exchange Commission on June 6, 2024

    Registration No. 333-             

    ​

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    FORM S-8

    ​

    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

    ​

    MARINUS PHARMACEUTICALS, INC.

    (Exact Name of Registrant as Specified in Its Charter)

    ​

    Delaware

        

    20-0198082

    (State or Other Jurisdiction of Incorporation
    or Organization)

    ​

    (I.R.S. Employer
    Identification No.)

    5 Radnor Corporate Center, Suite 500
    100 Matsonford Rd.
    Radnor, Pennsylvania

    ​

    19087

    (Address of Principal Executive Offices)

    ​

    (Zip Code)

    ​

    Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan

    Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended

    Individual Nonqualified Stock Option Awards (Inducement Grants)

    Individual Restricted Stock Units (Inducement Grants)

    (Full Title of the Plan)

    ​

    Steven E. Pfanstiel

    Chief Operating Officer and Chief Financial Officer

    Marinus Pharmaceuticals, Inc.

    5 Radnor Corporate Center, Suite 500

    100 Matsonford Rd.

    Radnor, Pennsylvania 19087

    (Name and Address of Agent For Service)

    ​

    (484) 801-4670

    (Telephone Number, Including Area Code, of Agent For Service)

    ​

    With Copies to:

    ​

    Steven J. Abrams
    Stephen M. Nicolai
    Hogan Lovells US LLP
    1735 Market Street, 23rd Floor
    Philadelphia, PA 19103
    (267) 675-4600

    Martha Manning

    Senior Vice President, General Counsel and Corporate Secretary
    Marinus Pharmaceuticals, Inc.
    5 Radnor Corporate Center, Suite 500
    100 Matsonford Rd.
    Radnor, Pennsylvania 19087

    ​

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    ​

    Large accelerated filer ☐

        

    Accelerated filer

    ☐

    ​

    ​

    ​

    ​

    Non-accelerated filer   ☒

    ​

    Smaller reporting company

    ☒

    ​

    ​

    ​

    ​

    ​

    ​

    Emerging growth company

    ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

    ​

    ​

    ​

    ​

    ​


    EXPLANATORY NOTE

    Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan

    This registration statement on Form S-8 is being filed by Marinus Pharmaceuticals, Inc., a Delaware corporation (the “Registrant”), to register 2,183,125 additional shares of the Registrant’s common stock, $0.001 par value per share (the “Common Stock”), issuable under the Registrant’s 2014 Equity Incentive Plan, as amended (the “2014 Plan”), which were added to the 2014 Plan on January 1, 2024 pursuant to the 2014 Plan’s “evergreen” provision.

    Pursuant to General Instruction E to Form S-8, and only with respect to the Common Stock being registered under the 2014 Plan, this registration statement incorporates by reference the contents of: (i) the registration statement on Form S-8 (File No. 333-200701) filed by the Registrant on December 3, 2014 relating to the 2014 Plan; (ii) the registration statement on Form S-8 (File No. 333-219613) filed by the Registrant on August 1, 2017 relating to the 2014 Plan; (iii) the registration statement on Form S-8 (File No. 333-233131) filed by the Registrant on August 8, 2019 relating to the 2014 Plan; (iv) the registration statement on Form S-8 (File No. 333-239785) filed by the Registrant on July 10, 2020 relating to the 2014 Plan; (v) the registration statement on Form S-8 (File No. 333-258677) filed by the Registrant on August 10, 2021 relating to the 2014 Plan; (vi) the registration statement on Form S-8 (File No. 333-265865) filed by the Registrant on June 28, 2022 relating to the 2014 Plan; and (vii) the registration statement on Form S-8 (File No. 333-272996) filed by the Registrant on June 29, 2023 relating to the 2014 Plan, in each case, except to the extent supplemented, amended or superseded by the information set forth herein.

    Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan

    This registration statement is also being filed to register an aggregate of 12,314,265 shares of Common Stock issuable under the Registrant’s 2024 Equity Incentive Plan (the “2024 Plan”), consisting of (a) 4,000,000 shares of Common Stock issuable under the 2024 Plan, and (b) a maximum of 8,314,265 shares of Common Stock that were subject to outstanding awards under the 2014 Plan (the “Outstanding Award Shares”) as of May 22, 2024, the effective date of the 2024 Plan. Pursuant to Section 4.1 of the 2024 Plan, the Outstanding Award Shares will become available for issuance under the 2024 Plan if such awards under the 2014 Plan are forfeited or otherwise terminated. The 2024 Plan was approved by the Registrant’s stockholders at the Registrant’s 2024 Annual Meeting of Stockholders on May 22, 2024.

    ​

    Inducement Awards

    This registration statement is also being filed to register an aggregate of 384,010 shares of Common Stock issuable upon the exercise of individual nonqualified stock option awards and upon vesting and settlement of restricted stock units granted to employees of the Registrant as an inducement material to entry into employment with the Registrant, in accordance with Nasdaq Listing Rule 5635(c)(4).

    ​

    ​

    ​

    ​


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    As permitted by the rules of the Securities and Exchange Commission (the “Commission”), this registration statement on Form S-8 omits the information specified in Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the participants in the plans covered by this registration statement as required by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”).

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.Incorporation of Documents by Reference.

    The following documents of the Registrant filed with the Commission are incorporated by reference in this registration statement as of their respective dates:

    (a)

    the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on March 5, 2024;

    (b)

    the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, filed with the Commission on May 8, 2024;

    (c)

    the Registrant’s Current Reports on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports that are related to such items), filed with the Commission on January 4, 2024, March 5, 2024, March 27, 2024, April 15, 2024, May 8, 2024, May 17, 2024, May 24, 2024 and June 6, 2024;

    ​

    (d)

    the information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023 from the Registrant’s Definitive Proxy Statement on Schedule 14A, filed with the Commission on April 4, 2024; and

    (e)

    the description of the Registrant’s securities included under the caption “Description of Registrant’s Securities” contained in the Registrant’s registration statement on Form 8-A, filed with the Commission on July 28, 2014, as updated by Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including any amendments or reports filed for the purpose of updating such description.

    All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), but prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents, except for the documents, or portions thereof, that are “furnished” rather than filed with the Commission.

    For the purposes of this registration statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

    Item 4.Description of Securities.

    Not applicable.

    ​


    Item 5.Interests of Named Experts and Counsel.

    Not applicable.

    Item 6.Indemnification of Directors and Officers.

    Section 102(b)(7) of the Delaware General Corporation Law (the “DGCL”) generally permits a Delaware corporation to provide in its certificate of incorporation that a director or officer of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except for liability for (i) with respect to directors and officers, any breach of the director’s or officer’s duty of loyalty to the corporation or its stockholders; (ii) with respect to directors and officers, acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) with respect to directors, payments of unlawful dividends or unlawful stock repurchases or redemptions under Section 174 of the DGCL; (iv) with respect to directors and officers, any transaction from which the director or officer derived an improper personal benefit; or (v) with respect to officers, any action by or in the right of the corporation.

    Section 145(a) of the DGCL provides, in general, that a Delaware corporation may indemnify any person who was or is a party, or is threatened to be made a party, to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) because that person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or other enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, so long as the person acted in good faith and in a manner he or she reasonably believed was in or not opposed to the corporation’s best interests, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

    Section 145(b) of the DGCL provides, in general, that a Delaware corporation may indemnify any person who was or is a party, or is threatened to be made a party, to any threatened, pending or completed action or suit by or in the right of the corporation to obtain a judgment in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or other enterprise. The indemnity may include expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action, so long as the person acted in good faith and in a manner the person reasonably believed was in or not opposed to the corporation’s best interests, except that no indemnification shall be permitted without judicial approval if a court has determined that the person is to be liable to the corporation with respect to such claim. Section 145(c) of the DGCL provides that, if a present or former director or officer has been successful in defense of any action referred to in Sections 145(a) and (b) of the DGCL, the corporation must indemnify such officer or director against the expenses (including attorneys’ fees) he or she actually and reasonably incurred in connection with such action.

    Section 145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or other enterprise against any liability asserted against and incurred by such person, in any such capacity, or arising out of his or her status as such, whether or not the corporation could indemnify the person against such liability under Section 145 of the DGCL.

    The Registrant’s fourth amended and restated certificate of incorporation and the Registrant’s amended and restated bylaws provide for the indemnification of its directors and officers to the fullest extent permitted under the DGCL.

    ​


    The Registrant has entered into separate indemnification agreements with all of its directors in addition to the indemnification provided for in the Registrant’s fourth amended and restated certificate of incorporation and the Registrant’s amended and restated bylaws. These indemnification agreements provide, among other things, that the Registrant will indemnify its directors for certain expenses, including damages, judgments, fines, penalties, settlements and costs and attorneys’ fees and disbursements, incurred by a director in any claim, action or proceeding arising in his or her capacity as a director of the Registrant or in connection with service at the Registrant’s request for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that a director makes a claim for indemnification.

    The Registrant also maintains a directors’ and officers’ insurance policy pursuant to which the Registrant’s directors and officers are insured against liability for actions taken in their capacities as directors and officers.

    Item 7.Exemption from Registration Claimed.

    Not applicable.

    ​

    ​


    Item 8.Exhibits.

    ​

    ​

    Exhibit

    No.

        

    Description

     

     

     

    4.1

     

    Fourth Amended and Restated Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 to Form 8-K current report filed on August 7, 2014.)

     

     

     

    4.2

     

    Certificate of Amendment of the Fourth Amended and Restated Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 to Form 8-K current report filed on April 2, 2020.)

     

     

     

    4.3

     

    Certificate of Amendment of the Fourth Amended and Restated Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 to Form 8-K current report filed on May 27, 2020.)

     

     

     

    4.4

     

    Certificate of Amendment of the Fourth Amended and Restated Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 to Form 8-K current report filed on September 22, 2020.)

     

     

     

    4.5

     

    Certificate of Amendment of the Fourth Amended and Restated Certificate of Incorporation. (Incorporated by reference to Exhibit 3.2 to Form 8-K current report filed on September 22, 2020.)

     

     

     

    4.6

     

    Amended and Restated By-laws. (Incorporated by reference to Exhibit 3.2 to Form 8-K current report filed on August 7, 2014.)

     

     

     

    4.7

     

    Delaware Certificate of Change of Registered Agent. (Incorporated by reference to Exhibit 3.8 to Form 10-Q quarterly report filed on May 12, 2022.)

     

     

     

    4.8

     

    Specimen Certificate evidencing shares of the Company’s common stock. (Incorporated by reference to Exhibit 4.1 to Form S-1/A registration statement filed on July 18, 2014.)

     

     

     

    5.1*

    ​

    Opinion of Hogan Lovells US LLP.

     

     

     

    10.1

    ​

    Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended. (Incorporated by reference to Exhibit 10.1 to Form S-8 registration statement filed on August 10, 2021.)

    ​

    ​

    ​

    10.2

    ​

    Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan. (Incorporated by reference to Exhibit 10.1 to Form 8-K current report filed on May 24, 2024.)

    ​

    ​

    ​

    10.3*

    ​

    Form of Nonqualified Stock Option Agreement for Non-Employee Directors under the Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan.

    ​

    ​

    ​

    10.4*

    ​

    Form of Restricted Stock Unit Agreement for Non-Employee Directors under the Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan.

    ​

    ​

    ​

    10.5*

    ​

    Form of Nonqualified Stock Option Agreement for Employees under the Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan.

    ​

    ​

    ​

    10.6*

    ​

    Form of Restricted Stock Unit Agreement for Employees under the Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan.

    ​

    ​

    ​

    10.7*

    ​

    Form of Nonqualified Stock Option Agreement for Employees granted as an Inducement Award under the Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan.

    ​

    ​

    ​

    10.8*

    ​

    Form of Incentive Stock Option Agreement for Employees under the Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan.

     

     

     

    23.1*

     

    Consent of Independent Registered Public Accounting Firm, Ernst & Young LLP.

    ​


     

     

     

    23.2*

     

    Consent of Hogan Lovells US LLP (included in Exhibit 5.1).

     

     

     

    24.1*

     

    Power of Attorney (included on signature page).

     

     

     

    107*

     

    Filing Fee Table.

    ​

    *

    Filed herewith.

    ​

    ​


    Item 9.Undertakings.

    (a)The undersigned Registrant hereby undertakes:

    (1)To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

    (i)To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment hereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective registration statement;

    (iii)To include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

    (2)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b)The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c)Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

    ​

    ​


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Radnor, Pennsylvania, on this 6th day of June, 2024.

    ​

    ​

    MARINUS PHARMACEUTICALS, INC.

    ​

    ​

    ​

    ​

    By:

    /s/ Scott Braunstein, M.D.

    ​

    Name:

    Scott Braunstein, M.D.

    ​

    Title:

    President and Chief Executive Officer

    ​

    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENT, that each person whose signature appears below hereby constitutes and appoints Scott Braunstein, M.D. and Steven E. Pfanstiel, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this registration statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or any of them or their substitutes, may lawfully do or cause to be done by virtue hereof.

    ​


    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.

    ​

    Signature

        

    Title

        

    Date

    ​

    ​

    ​

    ​

    ​

    /s/ Scott Braunstein, M.D.

    ​

    President, Chief Executive Officer (Principal Executive Officer), Chairman of the Board and Director

    ​

    June 6, 2024

    Scott Braunstein, M.D.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Steven E. Pfanstiel

    ​

    Chief Operating Officer, Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)

    ​

    June 6, 2024

    Steven E. Pfanstiel

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Charles Austin

    ​

    Director

    ​

    June 6, 2024

    Charles Austin

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Elan Ezickson

    ​

    Director

    ​

    June 6, 2024

    Elan Ezickson

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Seth H.Z. Fischer

    ​

    Director

    ​

    June 6, 2024

    Seth H.Z. Fischer

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Marvin H. Johnson, Jr.

    ​

    Director

    ​

    June 6, 2024

    Marvin H. Johnson, Jr.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Timothy M. Mayleben

    ​

    Director

    ​

    June 6, 2024

    Timothy M. Mayleben

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Saraswathy V. Nochur, Ph.D.

    ​

    Director

    ​

    June 6, 2024

    Saraswathy V. Nochur, Ph.D.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Sarah B. Noonberg, M.D., Ph.D.

    ​

    Director

    ​

    June 6, 2024

    Sarah B. Noonberg, M.D., Ph.D.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Christine B. Silverstein

    ​

    Director

    ​

    June 6, 2024

    Christine B. Silverstein

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​


    Get the next $MRNS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRNS

    DatePrice TargetRatingAnalyst
    9/23/2024$6.00Perform → Outperform
    Oppenheimer
    8/14/2024Buy → Neutral
    Ladenburg Thalmann
    4/16/2024$20.00 → $2.00Outperform → Neutral
    Robert W. Baird
    4/15/2024$24.00 → $3.00Outperform → Sector Perform
    RBC Capital Mkts
    8/11/2023$14.00 → $9.00Outperform → Perform
    Oppenheimer
    1/20/2023$23.00Outperform
    RBC Capital Mkts
    12/20/2021$32.00 → $30.00Outperform
    SVB Leerink
    More analyst ratings

    $MRNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ezickson Elan returned $5,995 worth of shares to the company (10,900 units at $0.55), closing all direct ownership in the company (SEC Form 4)

    4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

    2/11/25 9:19:58 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fischer Seth H. Z. returned $8,254 worth of shares to the company (15,007 units at $0.55), closing all direct ownership in the company (SEC Form 4)

    4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

    2/11/25 9:19:21 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF MEDICAL OFFICER Hulihan Joseph returned $39,999 worth of shares to the company (72,725 units at $0.55), closing all direct ownership in the company (SEC Form 4)

    4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

    2/11/25 9:18:26 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRNS
    SEC Filings

    View All

    SEC Form 15-12G filed by Marinus Pharmaceuticals Inc.

    15-12G - MARINUS PHARMACEUTICALS, INC. (0001267813) (Filer)

    2/21/25 8:00:27 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Marinus Pharmaceuticals Inc.

    SCHEDULE 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    2/14/25 4:00:04 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Marinus Pharmaceuticals Inc.

    EFFECT - MARINUS PHARMACEUTICALS, INC. (0001267813) (Filer)

    2/14/25 12:15:08 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN AND CEO Braunstein Scott bought $6,526 worth of shares (5,933 units at $1.10) and returned $167,530 worth of shares to the company (304,600 units at $0.55), closing all direct ownership in the company (SEC Form 4)

    4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

    2/11/25 9:11:48 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRNS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

    Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today announced that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus, by means of a tender offer and subsequent merger. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241230307666/en/ The acquisition complements and further strengthens Immedica's global rare disease business by adding ZTALMY® (ganaxalone) oral suspension, CV, a neuroactive steroid gamma-aminobuty

    12/30/24 7:00:00 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

    ZTALMY® (ganaxolone) Q3 2024 net product revenue of $8.5 million representing growth of 56% versus Q3 2023 Narrowing full year 2024 ZTALMY net product revenue guidance to $33 to $34 million Reported results from Phase 3 TrustTSC trial and commenced process to explore strategic alternatives Marinus continues to support the commercial growth of ZTALMY; further ganaxolone clinical development has been suspended Scheduled to meet with FDA Q4 2024 to discuss a potential path forward for IV ganaxolone in refractory status epilepticus Cost reduction plans implemented with cash runway expected into Q2 2025; cash and cash equivalents of $42.2 million as of September 30, 2024 Marin

    11/12/24 4:00:00 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

    Trial did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency (p=0.09); results showed numerically higher response rates for ganaxolone than placebo Ganaxolone was generally well-tolerated in TrustTSC with a safety profile consistent with previous clinical trials Cost reduction activities are underway Marinus has engaged Barclays as an advisor to assist with evaluating strategic alternatives Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures as

    10/24/24 8:00:00 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRNS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Marinus Pharmaceuticals upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Marinus Pharmaceuticals from Perform to Outperform and set a new price target of $6.00

    9/23/24 7:37:13 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marinus Pharmaceuticals downgraded by Ladenburg Thalmann

    Ladenburg Thalmann downgraded Marinus Pharmaceuticals from Buy to Neutral

    8/14/24 7:42:32 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marinus Pharmaceuticals downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Marinus Pharmaceuticals from Outperform to Neutral and set a new price target of $2.00 from $20.00 previously

    4/16/24 8:12:28 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

    SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/15/24 10:35:20 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Marinus Pharmaceuticals Inc.

    SC 13G - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/14/24 6:39:04 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

    SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/14/24 3:04:48 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRNS
    Financials

    Live finance-specific insights

    View All

    Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

    ZTALMY® (ganaxolone) Q2 2024 net product revenue of $8.0 million representing strong growth of 87% versus Q2 2023 On track to achieve full year 2024 ZTALMY net product revenue guidance of between $33 and $35 million Completed enrollment in the Phase 3 TrustTSC trial of oral ganaxolone in tuberous sclerosis complex (TSC) with topline data expected in the first half of Q4 2024 Expanded ZTALMY global footprint with activation of managed access programs for MENA, Russia and Canada with upcoming commercial launches anticipated in Europe and China Succeeded in post-grant review challenge of Ovid Therapeutics' U.S. Patent 11,395,817 for IV ganaxolone in the treatment of status epilept

    8/13/24 7:00:00 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ligand Reports Second Quarter 2024 Financial Results

    Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

    8/6/24 4:01:00 PM ET
    $AGEN
    $AMGN
    $CASI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024

    Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will host a conference call at 8:30 a.m. E.T. on August 13, 2024, to provide a business update and discuss financial results. Tuesday, August 13, 8:30 a.m. E.T. Domestic: (877) 405-1242 International: (201) 389-0852 Webcast Registration: Click Here An archived version of the call will be available approximately two hours after the completion of the event on the Marinus website at ir.marinuspharma.com/e

    7/30/24 8:00:00 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRNS
    Leadership Updates

    Live Leadership Updates

    View All

    DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

    Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

    1/22/24 8:23:00 AM ET
    $DMAC
    $MRNS
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.

    Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors. "Sarah is an accomplished healthcare executive with extensive global clinical development and corporate strategy experience," said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. "With a track record of successfully advancing programs in various therapeutic areas using diverse modalities, a deep understanding of orphan diseases and over a decade of experience as a hospitalist physician, her unique perspective will be invalu

    5/17/23 4:01:00 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors

    Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Marvin H. Johnson, Jr. to its Board of Directors. "With over 34 years of diverse commercial operations experience at Merck & Co., we are delighted that Marvin is joining the Marinus Board," said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. "His impressive background launching products across multiple therapeutic categories, including neurology and acute care, will be invaluable in supporting the continued commercial success of ZTALMY® and in preparing for a potential hospital

    4/18/23 7:01:00 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care